Skip to content

On this page

Susvimo

ranibizumab

351(a) Standalone BLA

Overview

Source: Purple Book

Proprietary name

Susvimo

Proper name

ranibizumab

Licence type

351(a)

BLA number

761197

Applicant

Genentech, Inc.

Center

CDER

Presentations

1

First licensure

—

Presentations

Source: Purple Book

Every strength and presentation recorded in the Purple Book for this product.
Strength	Dosage form	Route	Presentation	Status	Licensed
100MG/ML	Injection	Intravitreal	Single-Dose Vial	Rx	October 22, 2021

Sources for this page

Purple Book	FDA	Licence type, presentations, reference product, exclusivity